Acrivon Therapeutics
ACRV
63 hedge funds and large institutions have $45.7M invested in Acrivon Therapeutics in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 22 reducing their positions, and 7 closing their positions.
0% more funds holding
Funds holding: 63 → 63 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
2.84% less ownership
Funds ownership: 74.71% → 71.87% (-2.8%)
23% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 22
67% less capital invested
Capital invested by funds: $140M → $45.7M (-$94.3M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIA
Wealthedge Investment Advisors
New York
|
+$246K |
| 2 |
Invesco
Atlanta,
Georgia
|
+$190K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$78.5K |
| 4 |
PCM
Prelude Capital Management
New York
|
+$70.3K |
| 5 |
IIM
INTECH Investment Management
West Palm Beach,
Florida
|
+$54.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.21M |
| 2 |
Goldman Sachs
New York
|
-$969K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$794K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$677K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$470K |
ACRV Hedge Fund Activity: Q1 2025 in Review
63 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q1 2025, worth a combined $45.7M — down 67% from $140M a quarter earlier.
Fund positioning in ACRV was balanced in Q1 2025: 7 funds opened new positions, 7 closed out, 17 added to existing stakes and 22 trimmed.
The largest buyer was Wealthedge Investment Advisors, adding an estimated $246K. The largest seller was Citadel Advisors, cutting an estimated $1.21M.
- 63 institutional investors held Acrivon Therapeutics (ACRV) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $45.7M of Acrivon Therapeutics stock for Q1 2025, down 67% quarter-over-quarter.
- 7 funds opened new Acrivon Therapeutics positions in Q1 2025 and 7 closed out, a net change of 0 holders.
- The largest Acrivon Therapeutics buyer in Q1 2025 was Wealthedge Investment Advisors, an estimated $246K added.
- The largest Acrivon Therapeutics seller in Q1 2025 was Citadel Advisors, an estimated $1.21M sold.
Based on aggregated 13F filings for Q1 2025.